Itracource 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent effective against a wide range of fungal infections. It functions by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itracource 100 is primarily indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. The capsule formulation ensures optimal bioavailability and patient compliance. It is typically administered orally, with dosage and duration tailored to the severity and type of infection, as well as patient-specific factors such as age and hepatic function. Common side effects may include gastrointestinal disturbances, headache, dizziness, and transient elevations in liver enzymes; therefore, liver function monitoring is recommended during prolonged therapy. Itracource 100 should be used cautiously in patients with hepatic impairment and is contraindicated in individuals with known hypersensitivity to itraconazole or other azole antifungals. Concomitant use with certain drugs metabolized by cytochrome P450 enzymes may result in significant drug interactions. Healthcare professionals should evaluate the risk-benefit profile before initiating therapy and provide appropriate patient counseling regarding adherence and potential adverse effects.